4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million
FDMT•4D Molecular Therapeutics’ third-quarter net loss widened 37% year over year to $78.06 million, while collaboration and license revenue rose to $4.15 million. The company reported $375.03 million in cash, cash equivalents and marketable securities, with funding runway into the second half of 2028.
1. Quarterly results and outlook
4D Molecular Therapeutics’ third-quarter 2026 net loss widened 37% year over year to $78.06 million. Collaboration and license revenue rose to $4.15 million, primarily due to clinical trial cost sharing and reimbursement from Otsuka. Cash, cash equivalents and marketable securities totaled $375.03 million at September 30, and the company said its funding runway extends into the second half of 2028. Topline results from wet AMD trials 4FRONT-1 and 4FRONT-2 are expected in Q2 2027 and the second half of 2027, respectively; the company also initiated the global Phase 3 4SIGHT trial of 4D-150 in diabetic macular edema.
